Kailera Therapeutics Debuts on Nasdaq with $625M IPO, Backed by Hengrui’s Global GLP-1 Portfolio
Kailera Therapeutics, Inc. (NASDAQ: KLRA), a US-based biotech venture established in 2024 by China’s Jiangsu...
Kailera Therapeutics
Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs
Kailera Therapeutics has announced plans for an initial public offering (IPO) to secure additional funding...
Kailera Therapeutics Secures $600 Million Series B Funding from Bain Capital Private Equity to Accelerate Global Obesity Pipeline
Kailera Therapeutics, Inc., the Delaware‑registered spin‑off of Hengrui Pharma, today announced the closing of a...
Bain Capital to Acquire Tanabe Pharma in JPY 510 Billion Deal
Bain Capital is set to acquire Mitsubishi Tanabe Pharma Corporation (Tanabe Pharma) in a carve-out...
Hengrui and Kailera Announce Positive Phase II Results for HRS9531 in Weight Loss
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) and its US partner Kailera Therapeutics, Inc....
Kailera Therapeutics Emerges with USD 400 Million in Series A Funding for Anti-Obesity Pipeline
Kailera Therapeutics, a newly launched US-based biotechnology company, secured USD 400 million in Series A...